HIV-1-infected monocyte/macrophages located in lymph nodes and tissues are highly productive sources of HIV-1 and may function as a persistent reservoir contributing to the rebound viremia observed after highly active antiretroviral therapy is stopped. Mechanisms activating latently infected, primary monocyte/macrophages to produce HIV-1 were investigated using monocytes isolated from a transgenic mouse line carrying a full-length proviral clone of a monocyte-tropic HIV-1 isolate, HIV-1 JR-CSF , regulated by the endogenous long terminal repeat (LTR) (JR-CSF mice). Granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with lipopolysaccharide (LPS) induced infectious HIV-1 production by JR-CSF mouse monocytes over 10-fold and 100-fold higher than that stimulated by GM-CSF or LPS alone, respectively. We examined mechanisms of GM-CSF synergy with LPS and demonstrated that GM-CSF up-regulated the LPS receptor,
INTRODUCTION
A LTHOUGH ACTIVATED T CELLS ARE THE PREDOMINANT SOURCE OF HIV-1 in untreated patients, macrophages located in lymph nodes and tissues can also be highly productive sources of HIV-1, especially if coinfected with AIDS-associated pathogens such as Mycobacterium avium and Pneumocystis carinii. 1 Because highly active antiretroviral therapy (HAART) blocks HIV-1 replication in activated CD4 ϩ T cells far more efficiently than in chronically infected monocyte/macrophages, 2 HIV-1-infected monocyte/macrophages may be a major source of HIV-1 contributing to the recurrence of HIV-1 infection and the rebound viremia observed after the cessation of HAART. [3] [4] [5] [6] [7] Therefore, successful eradication of HIV-1 infection in patients will require the development of therapies that eliminate residual HIV-1 replication in monocyte/macrophages. Achievement of this goal would be facilitated by the delineation of the mechanisms that initiate long terminal repeat (LTR) transcription and induce viral production in HIV-1-infected monocyte/macrophages.
One factor reported to modulate HIV-1 production by monocytes is granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine produced rapidly by T cells, monocytes/macrophages, fibroblasts, and endothelial cells in response to infection by a broad range of pathogens. 8 GM-CSF stimulates the innate and adaptive immune responses by activating effector cells involved in antigen presentation and cellmediated immunity, particularly neutrophils, monocyte/macrophages, and dendritic cells. 9 The effect of GM-CSF on HIV-1 replication in monocyte/macrophages is complex and has been the subject of conflicting reports. 10 GM-CSF has been reported to either increase HIV-1 replication in primary monocyte/macrophages [11] [12] [13] [14] [15] and monocytic cell lines, [16] [17] [18] [19] or to inhibit HIV-1 production in primary monocyte/macrophages 20, 21 and monocytic cell lines. 22 While one study reported that GM-CSF potently increased HIV-1 entry and replication in primary monocytes by markedly increasing surface expression of CCR5, 15 another study reported that GM-CSF reduced HIV-1 entry and infection of primary monocytes/macrophages by down-regulating CCR5 expression. 23 Delineation of the effect of GM-CSF treatment on HIV-1-infected monocytes has important implications for the use of GM-CSF to treat HIV-1-infected patients. Clinical trials in untreated HIV-1-infected patients reported that GM-CSF therapy increased plasma levels of p24 antigen and HIV-1 RNA. [24] [25] [26] When combined with antiretroviral therapy, GM-CSF treatment was associated with decreased plasma HIV-1 mRNA levels in some studies, 27, 28 but not in other studies. [29] [30] [31] A recent large multicenter study reported that GM-CSF modestly increased plasma HIV-1 RNA levels in patients maintained on antiretroviral therapy. 32 If GM-CSF induces HIV-1 production, then it is likely that endogenous GM-CSF that is produced in response to infection may stimulate HIV-1 production in latently infected monocytes. Consequently, aside from understanding the therapeutic effect of GM-CSF on HIV-1-infection, delineating the effect of GM-CSF on HIV-1 replication may also provide insights into the role of GM-CSF in stimulating HIV-1 production from latently infected monocytes that reintroduces HIV-1 infection into the lymphoid tissues of patients taken off of HAART.
The biological behavior of cell lines differs from that of primary cells. Therefore further delineation of the effect of GM-CSF on HIV-1 replication in monocytes would be greatly facilitated by the availability of primary monocytes that are chronically infected with HIV-1. Mice have proven to be an extremely useful tool for investigating the pathogenesis of infectious diseases, the regulation of the immune system, and the generation of protective immunity. However, investigation of HIV-1 pathogenesis using mice has been limited by the inability of HIV-1 to infect mouse cells. 33, 34 The entry block preventing HIV-1 infection of mouse cells is due to the inability of the HIV-1 envelope protein, gp120, to bind to the murine homologues of human HIV receptors. 35 This block was circumvented by constructing mice carrying a provirus derived from an HIV-1 T-tropic laboratory isolate, NL4-3. 36,37 These mice have been used to evaluate in vivo activation of HIV-1 in monocytes by pathogens, [38] [39] [40] [41] the efficacy of treatments that block proviral expression, 42, 43 and the role of Toll-like receptors in pathogen-induced activation of the HIV-LTR. 44, 45 We developed a different transgenic mouse line carrying a fulllength HIV-1 provirus derived from the well-characterized, primary M-tropic clinical isolate, HIV-1 JR-CSF , under the control of the endogenous HIV-1 LTR (JR-CSF mice) populated with T cells, and monocytes that produce infectious HIV-1. 46 Because HIV-1 produced by the JR-CSF mouse monocytes cannot infect mouse cells, our transgenic mouse system permitted us to focus on the effect of factors that induce the postintegration phase of HIV-1 replication. We postulated that the LTRregulated proviral transgene would be inducible in JR-CSF mouse monocytes, and permit their use to identify factors that modulate HIV-1 production by primary monocytes/macrophages and to examine the effect of HIV-1 replication on monocyte/macrophage function. In this study we examined factors that induce HIV-1 JR-CSF provirus expression in monocytes from JR-CSF mice and demonstrated that treatment with GM-CSF markedly induces JR-CSF mouse monocytes to produce HIV-1 and significantly increases their capacity to produce HIV-1 in response to lipopolysaccharide (LPS) stimulation. Furthermore, we delineated the transduction pathways and transcription factors involved in the induction of HIV-1 by GM-CSF and LPS.
MATERIALS AND METHODS

Construction of JR-CSF transgenic mice
The JR-CSF transgenic mouse line was constructed as described with an infectious molecular clone of HIV-1 JR-CSF , PYK-JR-CSF (obtained from the NIH AIDS Research and Reference Reagent Program), derived from the lymphocytes of an HIV-infected patient soon after the initiation of culture. 46 This construct contains the full-length genomic sequence of HIV-1 JR-CSF as well as 0.5 kb of 3Ј and 2.2 kb of 5Ј flanking sequences, and produces infectious virions after transfection into cells. 47, 48 The PYK-JR-CSF plasmid was linearized with EcoRI, and then microinjected into the pronuclei of fertilized embryos derived from FVB ϫ C57/B6 mouse crosses as described. 49 Transgenic mice were identified by polymerase chain reaction (PCR) analysis of genomic DNA extracted from tails using primer pairs specific for the amplification of HIV-1 gag DNA as described. 46 
Isolation of monocytes from the mouse bone marrow
Mouse femurs were flushed with phosphate-buffered saline (PBS) and cells were isolated from the extracted bone marrow by dispersal with vigorous pipetting. The bone marrow cells were harvested, washed, resuspended in complete media [RPMI media containing 10% fetal calf serum (FCS) and 2-mercaptoethanol (50 M)], and cultured in 100-mm petri dishes at a density of 2 ϫ 10 6 cells/ml. After overnight culture, the nonadherent cells were gently rinsed away and discarded. Fresh RPMI media containing 10% FCS and 2-mercaptoethanol (50 M) chilled to 4°C was added and the adherent cells were harvested by scraping. The adherent cells were washed and were Ͼ95% viable by trypan blue exclusion and Ͼ95% of the cells expressed the monocyte marker CD11b.
Flow cytometric analysis
Monocytes harvested from the bone marrow of the mice as described above were stained with a fluorescein isothiocyanate (FITC)-conjugated rat monoclonal antibody to mouse CD11b, PE-conjugated rat monoclonal antibody to mouse CD14 (BD Biosciences Pharmingen, San Diego, CA), or PE-conjugated rat monoclonal antibody to mouse TLR-4 (clone HTA125; eBiosciences, San Diego, CA). 50 Expression of surface proteins was assessed by flow cytometric analysis using a FACScan cell analyzer with LYSIS-II software (Becton Dickinson). Forward and side scatter profiles were used to gate out nonviable cells and gate in monocytes/macrophages.
Evaluation of the infectivity of JR-CSF mouse monocytes
Monocytes isolated from the bone marrow of JR-CSF mice as described above were cultured in 24-well plates (5 ϫ 10 5 cells/well) with phytohemagglutinin (PHA)-activated human donor PBMCs (1 ϫ 10 6 cells/well) in complete media containing interleukin (IL)-2 (25 units/ml) as described. 46 One to two weeks later, the p24 antigen content of the culture supernatant was measured at the indicated times using the HIV-1 p24 core profile enzyme-linked immunosorbent assay (ELISA) (PerkinElmer Life Sciences Inc., Boston, MA) as described. 46 
Quantification of HIV production by stimulated monocytes
Monocytes (10 5 cells) isolated from the bone marrow of JR-CSF mice were cultured in duplicate in 96-well plates in complete media alone or with added GM-CSF (20 ng/ml) in a total volume of 200 l. After 24 hr, LPS (1 g/ml) was added to some of the cultures. At the indicated time, HIV-1 produced by the JR-CSF mouse monocytes was quantified by measuring the p24 antigen content of the culture supernatant.
Detection of HIV gene expression by RT-PCR
Total RNA (6 g) was extracted from the indicated cells using the Qiagen RNeasy kit and was digested with 5 U of DNase I (Roche) in the presence of 20 U of recombinant RNasin (Promega). Reverse transcription (RT)-PCR was performed on an aliquot of total RNA (100 ng), using the one-step RT-PCR kit (Qiagen, Valencia, CA). After performing the reverse transcription reaction for 30 min at 50°C, tat, rev, and nef mRNA were detected by PCR using specific primer pairs. Tat mRNA was detected using the primers 5Ј-GGCGGATCC ATG-GAGCCAGTAGATCCT-3Ј and 5Ј-GCCGAATTCCTATTC-CTTCGGGCCTGT-3Ј as described. 51 Rev and Nef mRNA were detected using the primer pair US (5Ј-TCTCTC-GACGCAGGACTCGGCTTGC-3Ј) and ART7 (5Ј-TTC-TATTCCTTCGGGCCTGTCG-3Ј) that span splice junctions to amplify the doubly spliced mRNA encoding the Rev and Nef proteins and yield amplified products of 197 and 181 bp, respectively. 52, 53 Basal mRNA production was determined using primers for the 18S mRNA as described. 54 The initial PCR reaction was done at 95°C for 15 min followed with 35 cycles of denaturation at 95°C for 1 min, annealing at 62°C for 1 min, and primer extension at 72°C for 1 min. The final cycle included a 10 min extension at 72°C. Amplified products were separated by electrophoresis on a 2% agarose gel containing ethidium bromide, detected under ultraviolet light, and quantified by densitometry using the Kodak Image Station and 1D Software (Kodak, Rochester, NY).
Determination of the in vivo infectivity of JR-CSF mouse monocytes using thy/liv-SCID-hu mice
SCID mice (6-8 weeks old) were implanted with human fetal thymic and liver tissue under their kidney capsules to generate thy/liv-SCID-hu mice as described. 50 Briefly, after SCID mice were anesthetized with pentobarbital (40-80 mg/kg), five pieces each of syngeneic human fetal thymic and liver tissue were implanted under the kidney capsules. Three months later, the size of the implanted human tissue had usually increased by greater than 20-fold. Thy/liv-SCID-hu mice were infected by direct injection of 2.5 ϫ 10 6 GM-CSF-treated monocytes in a volume of 30 l into the human thymic graft implant. Infection of the human thymic implants was quantified by limiting dilution coculture of thymocytes isolated from the graft with activated human PBMCs and measuring the concentration of p24 antigen present in the culture supernatant 1-2 weeks later as described. 50, 55 The consent forms and procedures used in this study were reviewed and approved by the Albert Einstein College of Medicine Committee on Clinical Investigation and by the Animal Institute Committee.
Evaluation of mitogen-activated protein (MAP) kinase expression by Western immunoblotting
Monocytes isolated from the bone marrow were stimulated as indicated, harvested, washed with PBS, centrifuged, and the pelleted cells were resuspended in 200 l of lysis buffer [20 mM tris-acetate (pH 7.0), 270 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10 mM sodium ␤-glycerophosphate, 50 mM NAF, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM benzamidine, 4 g/ml leupeptin, 0.1% 2-mercaptoethanol] as described. 56 The cells were mixed vigorously, put through two cycles of freezing, thawing, and vigorous mixing, spun for 5 min at 13,000 rpm in a microfuge, and the supernatant containing the membrane and cytosol fractions was harvested. The protein concentration of the supernatant was determined using a Bio-Rad Protein assay according to the manufacturer's protocol (Bio-Rad, Hercules, CA). A fraction of the cellular lysate (20 g of protein) from each sample was separated on a NuPage SDS Bis-Tris 4-12% gel (Invitrogen, Carlsbad, CA) and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). The membrane was incubated with an affinity-purified polyclonal rabbit antibody (Anti-ACTIVE MAP KINASE pAb, Rabbit, Promega, Madison, WI) that specifically recognizes the dually phosphorylated, active forms of extracellular signal-regulated kinase (ERK)1 and ERK2. Bound antibody was detected with the Western Lightning chemiluminescence system (Perkin-Elmer, Boston, MA) according to the manufacturer's protocol. Specific bands located at the predicted molecular weights for ERK1 and ERK2, 44 and 42 kDa, were quantified by densitometry using AMBIS Radioanalytic Imaging System Quant-Probe Software (AMBIS, Inc., San Diego, CA).
Nuclear extract preparation
Monocyte nuclei were isolated and extracted as described. 57, 58 Isolated mouse monocyte nuclei were resuspended in about 100 l of nuclear extract buffer [10 mM HEPES (pH 8.0), 0.5 M NaCl, 0.125 mM EDTA, 0.1 mM EGTA, 0.5 mM spermidine, 0.15 mM spermine, 25% glycerol, 1 mM PMSF, 10 mM benzamidine, 7 mM 2-mercaptoethanol, 0.28 g/ml pepstin, and 5 g/ml leupeptin]. While the samples were incubated on ice for 30 min, they were mixed at 5 min intervals. The samples were clarified by centrifugation at 10,000 ϫ g for 15 min. The supernatants containing the nuclear extract were dialyzed to binding buffer using a Slide-A-Lyzer Mini Dialysis Unit (Pierce, Rockford, IL) at 4°C for 10 min and the protein concentration in the supernatants was measured with a BCA Protein Assay Reagent Kit (Pierce). The binding reactions were carried out as described 59 at room temperature in gel shift buffer for NF-B [1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES (pH 7.9), 50 mM NaCl 2 , 15 mM 2-mercaptoethanol, 10% glycerol, 0.01% bovine serum albumin, and 0.1% poly(dl-dC)], C/EBP [34 mM KCl, 5 mM MgCl 2 , 0.1 mM dithiothreitol, and 0.015% g of poly(dl-dC)], or Sp1 [1 mM CaCl 2 , 1 mM MgCl 2 , 5 mM dithiothreitol, 5 mM EDTA, 10 mM HEPES (pH 7.9), 1.5 mM NaCl, 150 mM KCl, 1 mM ZnSO 4 , 0.1% bovine serum albumin, 10% glycerol, 0.05% poly(dl-dC)] for 30 min. Protein-DNA complexes were separated on a 5% (for NF-B binding complexes) or 4.5% (for C/EBP and Sp1 binding complexes) nondenaturing polyacrylamide gel in Tris-glycine-EDTA buffer (25 mM Tris, 200 mM glycine, and 1 mM EDTA) and visualized by autoradiography of the dried gel. Specific bands indicating the binding complexes were quantified by densitometry using the IQmac Image Quant Program (Molecular Dynamics, Sunnyvale, CA). For competition analysis, either unlabeled or mutant oligonucleotides (50ϫ) were incubated with the nuclear extract before addition of the labeled probe.
Gel mobility shift assays
Statistical analysis of the data
The Student's t test for unpaired data was used for all statistical comparisons made. Significance was assigned for p Ͻ 0.05.
RESULTS
HIV-1 production by JR-CSF mouse monocytes is markedly enhanced by treatment with GM-CSF
The HIV-1 LTR controls expression of the JR-CSF transgene in JR-CSF mouse cells and factors that activate the HIV LTR should increase HIV-1 production. To determine whether JR-CSF mouse monocytes could be used to study the regulation of HIV-1 replication in monocytes, we examined whether HIV-1 production by these cells was induced by stimulation with monocyte-activating factors as reported for the chronically infected monocyte/macrophage-like cloned cell line U1. 19 Therefore we examined the effect of GM-CSF treatment alone and combined with LPS, IL-1, and tumor necrosis factor (TNF)-␣ on HIV-1 production by JR-CSF mouse monocytes. Monocytes isolated from JR-CSF mouse bone marrow were placed in culture and either left untreated or treated with GM-CSF. Twenty-four hours later, some of the cultures were stimulated with either LPS, IL-1, or TNF␣ and 5 days later HIV-1 production by the cells was determined by measuring the p24 antigen concentration in the supernatant. While unstimulated JR-CSF mouse monocytes or JR-CSF mouse monocytes stimulated with either LPS, IL-1, or TNF␣ did not produce detectible levels of HIV-1, GM-CSF treatment significantly (p Ͻ 0.015) stimulated HIV-1 production by the JR-CSF mouse monocytes (Fig. 1A) . GM-CSF-induced HIV-1 production was not increased by the addition of IL-1 (p Ͻ 0.32) or TNF-␣ (p Ͻ 0.52), but was significantly increased (p Ͻ 0.00002) almost 20-fold when combined with LPS stimulation (Fig. 1A) . Thus, measurement of HIV-1 production by JR-CSF mouse monocytes indicated that expression of the HIV-1 LTR-regulated JR-CSF transgene was minimally stimulated by LPS alone, moderately stimulated by GM-CSF alone, and markedly stimulated by the combination of LPS and GM-CSF.
Because an HIV-1 assembly block in mouse cells may prevent efficient release of HIV-1 particles, 35 we needed to determine whether GM-CSF and LPS increased secretion of HIV-1 sequestered in the cell or induced the production of newly synthesized HIV-1. Therefore, HIV-1 production and secretion were evaluated by measuring p24 antigen concentration in cellular lysates and in the culture supernatant after stimulation of JR-CSF mouse monocytes with GM-CSF alone or with GM-CSF and LPS. After 7 days, the concentration of p24 antigen in the culture supernatant of GM-CSF-stimulated and GM-CSF/LPS-stimulated JR-CSF mouse monocytes was almost 10-fold higher than in the cell lysate (Fig. 1B) . This indicated that JR-CSF mouse monocytes efficiently secreted HIV-1 into the supernatant and GM-CSF and LPS directly stimulated HIV-1 production.
JR-CSF monocytes produce infectious HIV-1
We next determined whether the HIV-1 produced by JR-CSF mouse monocytes after GM-CSF treatment and LPS stimulation was infectious. JR-CSF mouse monocytes were stimulated with GM-CSF and LPS, and the culture supernatant was collected 5 days later and added to new cultures containing activated human PBMC. The p24 antigen content of the supernatant was measured 7, 14, and 28 days after the initiation of the coculture. The marked increase in p24 antigen production observed during the course of the coculture indicated that the HIV-1 produced by the JR-CSF mouse monocytes was infectious (Fig. 2) . The infectivity of HIV-1 produced by the GM-CSFstimulated JR-CSF monocytes was further characterized by determining whether stimulated JR-CSF mouse monocytes would initiate in vivo HIV-1 infection in thy/liv-SCID-hu mice. JR-CSF mouse monocytes (3 ϫ 10 6 cells) were treated with GM-CSF and directly injected into the human thymic implants of thy/liv-SCID-hu mice (n ϭ three mice). One month later, the human thymic implants of the mice were biopsied, and HIV-1 infection in the human thymic grafts was quantified by performing limiting dilution coculture of the isolated human thymocytes with PHA-activated donor mononuclear cells and determining the lowest number of thymocytes capable of initiating productive HIV-1 infection. The implants from all of the mice were extensively infected with HIV-1, with productive infection in the donor mononuclear cells detected after addition of as few as 1600 thymocytes from each of the human thymic implants. Thus, monocytes from the JR-CSF mice produce infectious HIV-1 capable of initiating in vitro and in vivo infection.
GM-CSF stimulates HIV-1 gene expression in monocytes
The effect of GM-CSF and LPS stimulation on HIV-1 mRNA expression by JR-CSF mouse monocytes was examined by isolating monocytes from the bone marrow of JR-CSF mice and either culturing the cells in media alone or stimulating the cells with GM-CSF or GM-CSF and LPS for 1 day. RNA was extracted from the cells, treated with DNase, and the expression of specific HIV genes was determined by amplification of viral DNA by RT-PCR assays utilizing primer pairs used to measure tat, rev, and nef mRNA expression in HIV-1-infected monocytes. [51] [52] [53] As shown in Fig. 3 , low levels of mRNA encoding Tat, Rev, and Nef detected in unstimulated JR-CSF mouse monocytes increased after GM-CSF treatment and further increased after stimulation of the GM-CSF-treated cells with LPS. Thus, the increased expression of HIV-1 mRNA after treatment with GM-CSF and LPS indicated that the combination of these factors was a more potent activator of the HIV-1 LTR.
Treatment of monocytes with GM-CSF up-regulates TLR-4 expression
The innate immune system is activated by the binding of microbial factors to Toll-like receptors (TLR) such as zymosan, peptidoglycan, and lipoarabinomannan binding to TLR-2 and LPS interacting with TLR-4. 60 The expression of TLR-2 by neutrophils is markedly increased by GM-CSF, thereby increasing their responsiveness to zymosan, peptidoglycan, and lipoarabinomannan. 61 We hypothesized that GM-CSF treatment 
FIG. 2.
JR-CSF mouse monocytes produce infectious HIV-1. Supernatant from JR-CSF bone marrow-derived monocytes stimulated with GM-CSF (20 ng/ml) and LPS was harvested, filtered, and then added to cultures of activated human donor PBMC (1 ϫ 10 6 cells) in 24-well plates. An aliquot of culture supernatant was harvested 7, 14, and 28 days later and the concentration of p24 antigen was determined. The data from two independent experiments using bone marrow-derived monocytes isolated from different groups of JR-CSF mice are shown as the mean Ϯ SEM of p24 antigen production in duplicate cultures.
increased the responsiveness of JR-CSF monocytes to LPS stimulation by up-regulating the surface expression of TLR-4. To examine this possibility, monocytes were isolated from the bone marrow of JR-CSF mice, and the effect of GM-CSF treatment on surface expression of TLR-4 by monocytes was measured by flow cytometry. Cultured monocytes displayed low levels of TLR-4 expression that were minimally increased by stimulation with LPS (Fig. 4) . In contrast, GM-CSF treatment markedly increased the surface expression of TLR-4. Thus, upregulation of TLR-4 expression may be one mechanism by which GM-CSF increases the capacity of LPS to stimulate HIV-1 production by JR-CSF monocytes.
Effect of signal transduction inhibitors on the stimulation of HIV-1 production by GM-CSF and LPS
The GM-CSF receptor is a member of the IL-3/IL-5/GM-CSF receptor family characterized by the common structural motif of a heterodimer that consists of a cytokine-specific ␣-chain and a common ␤-chain. 62 GM-CSF binds to its multichain receptor and activates several signal transduction routes that include the ERK and p38 MAP kinase signaling pathways and the phosphatidylinositol (PI) 3-kinase-regulated pathway. 63 the ERK and p38 MAP kinase cascades. 60, 65, 66 To identify signal transduction pathways involved in HIV-1 production induced by GM-CSF and LPS, we used specific inhibitors of p38 MAP kinase, SB203580 and SB202190, 67 MAP kinase/ERK kinase (MEK), PD98059, 68, 69 and PI 3-kinase, LY294002. 70 Signal transduction pathways involved in GM-CSF-stimulated HIV-1 production by the JR-CSF mouse monocytes were evaluated by examining the effect of the indicated inhibitors on p24 antigen production by the JR-CSF mouse monocytes. HIV-1 production by the GM-CSF-stimulated JR-CSF mouse monocytes was suppressed significantly by specific inhibitors of p38 MAP kinase (p Ͻ 0.0016), MEK (p Ͻ 0.0063), and PI 3-kinase (p Ͻ 0.00006) (Fig. 5) . To examine the signal transduction pathways used by the combination of GM-CSF and LPS, the specific inhibitors of p38 MAP kinase, MEK, and PI 3-kinase were added either at the same time as GM-CSF or on the next day along with LPS. HIV-1 production by JR-CSF mouse monocytes was determined 3 days later. When the inhibitors were added concurrently with GM-CSF, HIV-1 production by the JR-CSF mouse monocytes was potently suppressed by specific inhibitors of p38 MAP kinase (p Ͻ 0.002) and MEK (p Ͻ 0.002) and moderately suppressed by the PI 3-kinase inhibitor (Fig. 6A) . When the inhibitors were added 1 day after GM-CSF and contemporaneously with LPS, specific inhibitors of p38 MAP kinase (p Ͻ 0.000002) and MEK (p Ͻ 0.0002) potently suppressed HIV-1 production by the JR-CSF mouse monocytes (Fig. 6B) . In contrast, the PI 3-kinase inhibitor did not affect LPS-stimulated HIV-1 production by the GM-CSFtreated JR-CSF mouse monocytes.
GM-CSF and LPS induce phosphorylation of ERK1 and ERK2
The direct effect of GM-CSF and LPS on the activation of the ERK pathway was examined by determining the phosphorylation status of ERK1 and ERK2 after stimulation with GM-CSF and/or LPS using Western blot analysis. These studies were performed using an antibody specific for phosphorylated ERK1/ERK2 on cellular extracts isolated from bone marrow-derived monocytes that were stimulated as indicated (Fig.  7) . Minimal ERK1/ERK2 phosphorylation was observed in monocytes cultured in media for 24 hr or stimulated with LPS for 1 hr. After 24 hr, GM-CSF markedly stimulated ERK1/ERK2 phosphorylation that was further increased 2-fold by costimulation with LPS for 1 hr. Thus, as observed for HIV-1 production, the combination of GM-CSF and LPS was a more potent inducer of MAP kinase activation than was GM-CSF or LPS alone. 
HIV PRODUCTION BY MONOCYTES FROM HIV TRANSGENIC
Treatment of mouse monocytes with GM-CSF increases NF-B, CCAATT/enhancer binding protein (C/EBP) ␤, and Sp1 binding activity in nuclear extracts
The expression of the HIV-1 provirus is tightly controlled by cellular transcription factors such as NF-B, C/EBP ␤, and Sp1 that bind to cis-acting DNA sequences within the HIV-1 LTR. 71 Increased HIV-1 production after stimulation by LPS and GM-CSF by U1, a chronically infected monocyte/macrophage cloned cell line, was associated with activation of NF-B in one study, 19 but not in another. 17 Therefore, we investigated the effect of LPS and GM-CSF on NF-B activation in primary mouse monocytes. Monocytes harvested from the bone OSIECKI ET AL. 132   FIG. 6 . GM-CSF augmentation of LPS-stimulated HIV-1 production is suppressed by kinase inhibitors. Purified monocytes were cultured in duplicate in 96-well plates in the presence of GM-CSF (20 ng/ml). Twenty-four hours later, LPS was added to the cultures. The indicated inhibitors were either (A) added at the initiation of culture or (B) added 24 hr after the initiation of culture concurrent with the addition of LPS. Seventy-two hours after the addition of LPS, the p24 antigen concentration in the supernatant was determined. The percentage suppression was calculated as [100 Ϫ [100 ϫ (p24 antigen production in the presence of the inhibitor/p24 antigen production with no added inhibitor)]]. The data shown represent the mean Ϯ SEM percentage suppression of four independent experiments performed in duplicate. marrow were either untreated or treated with GM-CSF for 24 hr. The next day a fraction of the untreated and GM-CSF-treated cells was stimulated with LPS for 4 hr. NF-B binding activity was not detected by the electrophoretic mobility shift assay in the nuclear extracts of unstimulated monocytes isolated after 24 hr of culture, was weakly induced by stimulation with LPS, and was potently stimulated to an equivalent level by treatment with GM-CSF and the combination of GM-CSF and LPS (Fig. 8) . Because HIV-1 replication in monocyte/macrophage lineage cells is dependent on the activation of C/EBP ␤ binding sites located in the HIV-1 LTR, 72, 73 we also examined the effect of GM-CSF and LPS on C/EBP induction. As shown in Fig. 9 , C/EBP ␤ binding activity was not detected in unstimulated monocytes, was moderately induced by LPS, and was strongly stimulated by GM-CSF to a level that was only minimally increased by about 1.5-fold when combined with LPS. We also examined the effect of LPS and GM-CSF on the induction of Sp1, whose binding site has been shown to be involved in GM-CSF activation of the HIV-1 LTR. 74 As shown in Fig. 10 , while the basal levels of Sp1 binding activity detected in unstimulated monocytes were only mildly increased by LPS (1.1-fold) or GM-CSF (2.1-fold), Sp1 binding activity was potently stimulated by the combination of GM-CSF and LPS (6.5-fold). Thus, while LPS did not markedly increase GM-CSF-induced nuclear localization of NF-B and C/EBP, LPS markedly increased GM-CSF-stimulated nuclear expression of Sp1, a transcription factor shown to play a crucial role in HIV-1 transcription in monocytes. 
HIV PRODUCTION BY MONOCYTES FROM HIV TRANSGENIC
DISCUSSION
Latently infected monocyte/macrophages are a major potential reservoir of HIV-1-infected cells in patients that is capable of reintroducing systemic infection after the cessation of HAART. [3] [4] [5] [6] Because unstimulated mouse monocytes isolated from the JR-CSF mouse line that carry an HIV-1 provirus under the control of the endogenous LTR do not produce detectible virus, they exhibit some of the characteristics of latently infected cells. Consequently, we utilized JR-CSF mouse monocytes to gain insight into the mechanisms by which latently infected primary monocytes/macrophages that may function as persistent reservoirs of HIV-1 infection become activated to produce HIV-1. In the current study we demonstrated that HIV-1 was efficiently secreted by the JR-CSF monocytes after stimulation with GM-CSF and LPS and the virus produced was infectious. This contrasts with studies detecting inefficient production of HIV-1 by the mouse fibroblastic cell line, NIH 3T3, OSIECKI ET AL. 134   FIG. 8 . Effect of LPS, GM-CSF, and the combination of LPS and GM-CSF on NF-B activity. Purified monocytes were either cultured without stimulation, stimulated with LPS (1 g/ml) for 4 hr, treated with GM-CSF (20 ng/ml) for 24 hr, or treated with GM-CSF (20 ng/ml) for 24 hr followed by LPS stimulation for 4 hr. (A) After centrifugation and collection of cell pellets, nuclear extracts were harvested and EMSA was performed using nuclear extracts containing 5 g of proteins incubated for 1 hr with 32 P-labeled oligonucleotides corresponding to the consensus sequence for NF-B. (B) Competition assays were performed to demonstrate the specificity of NF-B transcription factor binding, by incubating the nuclear extracts from activated cells with a 50-fold molar excess of either a cold wild-type competitor oligonucleotide or a cold mutant noncompeting oligonucleotide. The specific complex was completely abolished when the wild-type probe was added, but persisted when the mutated probe was added. Results are representative of the analysis of two separate experiments.
FIG. 9.
Effect of LPS, GM-CSF, and the combination of LPS and GM-CSF on C/EBP activity. Purified monocytes were either cultured without stimulation, stimulated with LPS (g/ml) for 4 hr, treated with GM-CSF (20 ng/ml) for 24 hr, or treated with GM-CSF (20 ng/ml) for 24 hr followed by LPS stimulation for 4 hr. (A) After centrifugation and collection of cell pellets, nuclear extracts were harvested and EMSA was performed using nuclear extracts containing 5 g of proteins incubated for 1 hr with 32 P-labeled oligonucleotides corresponding to the consensus sequence for C/EBP. The band intensity was measured by densitometry. (B) Competition assays were performed to demonstrate the specificity of C/EBP transcription factor binding, by incubating the nuclear extracts with a 50-fold molar excess of either a cold wild-type competitor oligonucleotide or a cold mutant noncompeting oligonucleotide. The specific complex was completely abolished when the cold wild-type probe was added, but persisted when the mutated probe was added. Results are representative of the analysis of two separate experiments.
that led investigators to conclude that mouse cells are unable to efficiently assemble HIV-1 due to a species-specific block. 35, 75, 76 These disparate results may be a consequence of different mechanisms for HIV-1 assembly used by T cells and 3T3 cells compared to that utilized by monocytes. In T cells and 3T3 cells, the primary location for HIV-1 assembly is the plasma membrane where a block to assembly of HIV-1 may exist in mouse cells. In contrast, the major location of HIV-1 assembly in monocytes is in the late endocytic membranes. 77 HIV-1 assembly in late endocytic membranes may be via a different mechanism from that occurring at the plasma membrane thereby permitting HIV-1 to circumvent the block that prevents efficient assembly on the plasma membrane of mouse cells. This would account for the efficient production of HIV-1 by JR-CSF mouse monocytes that we observed.
In addition to directly inducing HIV-1 production, GM-CSF also synergized with LPS to induce HIV-1 production to levels that were over 10-fold higher than that stimulated by GM-CSF alone and over 100-fold higher than that induced by LPS alone. These results are compatible with previous reports that LPS induction of HIV-1 production by the chronically infected monocyte/macrophage cell line, U1, was significantly enhanced by treatment with GM-CSF. 17, 19 The mechanism for the synergistic effect of GM-CSF on LPS-induced HIV-1 production by U1 cells was attributed to up-regulation of expression of CD14, a component of the LPS receptor. 17, 78 Since publication of those studies, TLR-4 has been identified as the LPS signal transducer molecule and shown to be the limiting factor for LPS signal transduction in mouse macrophages. 79 We hypothesized that GM-CSF increased the responsiveness of JR-CSF mouse monocytes to LPS by up-regulating TLR-4, a mechanism comparable to that reported for GM-CSF enhancement of neutrophil responsiveness to TLR-2 ligands. 61 Flow cytometric analysis of JR-CSF mouse monocytes demonstrated that treatment with GM-CSF markedly increased the expression of the TLR-4/MD-2 signaling complex. These findings indicated that induction of TLR-4 expression might contribute to the capacity of GM-CSF to increase the responsiveness of the JR-CSF mouse monocytes to LPS.
There is significant overlap between the signal transduction pathways induced by GM-CSF and LPS, with activation of the PI 3-kinase pathway, the Raf/ERK/MAP kinase pathway, and the p38 mitogen-activated kinase and the NF-B pathway by GM-CSF [80] [81] [82] [83] and by LPS. 66 Therefore, we investigated whether GM-CSF also enhanced LPS activity by providing additive stimulation of these common signal transduction pathways. Inhibitors of either MEK, p38 MAP kinase, or PI 3-kinase suppressed GM-CSF-induced HIV-1 production by JR-CSF mouse monocytes, which indicated that all of these pathways were involved in the activation of HIV-1 replication by GM-CSF. In contrast, a study using a mouse B cell line, Ba/F3, transfected with constructs encoding the human GM-CSF receptor and an HIV-1 LTR reporter gene, reported that GM-CSF-induced activation of the HIV-1 LTR was inhibited by the PI 3-kinase inhibitor, wortmannin, but not by the same MEK inhibitor we used, PD98059. 74 Our results using primary monocytes may differ from those reported in that study using lymphoid cell lines because different signal transduction pathways may be activated by GM-CSF in primary monocytes versus lymphoid cell lines. This possibility is compatible with the finding that activation and binding of the C/EBP transcriptional activator to its binding sites in the HIV-1 LTR are required for HIV-1 replication in monocytes, but not in T cells. 72, 73 The signal transduction pathways responsible for GM-CSF enhancement of the responsiveness of monocytes to LPS stimulation were also evaluated by adding inhibitors either at the initiation of GM-CSF treatment or 1 day later concurrent with the addi-
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FIG. 10.
Effect of LPS, GM-CSF, and the combination of LPS and GM-CSF on Sp1 activity. Purified monocytes were either cultured without stimulation, stimulated with LPS (g/ml) for 4 hr, treated with GM-CSF (20 ng/ml) for 24 hr, or treated with GM-CSF (20 ng/ml) for 24 hr followed by LPS stimulation for 4 hr. (A) After centrifugation and collection of cell pellets, nuclear extracts were harvested and EMSA was performed using nuclear extracts containing 5 g of proteins incubated for 1 hr with 32 P-labeled oligonucleotides corresponding to the consensus sequence for Sp1. The band intensity was measured by densitometry. (B) Competition assays were performed to demonstrate the specificity of Sp1 transcription factor binding, by incubating the nuclear extracts with a 50-fold molar excess of either a cold wild-type competitor oligonucleotide or a cold mutant noncompeting oligonucleotide. The specific complex was completely abolished when the cold probe was added, but persisted when the mutated probe was added. Results are representative of the analysis of three separate experiments.
tion of LPS. Inhibition of MEK and p38 MAP kinase, but not PI 3-kinase, potently inhibited HIV-1 production induced by LPS after GM-CSF treatment. These results indicated that the PI 3-kinase pathway is not integral to the signal provided by GM-CSF to enhance LPS-induced HIV-1 production or to the pathway used by LPS to stimulate HIV-1 production. Inhibition of either MEK or p38 MAP kinase suppressed both GM-CSF and LPS-induced HIV production by JR-CSF mouse monocytes, indicating that activation of both of these pathways contributes to the synergistic effects of GM-CSF and LPS. Sequence-specific host transcription factors bind to cis-acting elements present in the HIV-1 LTR and contribute to the tight regulation of HIV-1 proviral gene expression. 71 NF-B and Sp1 were identified as the host transcription factors responsible for GM-CSF induction of HIV-1 LTR by mutational analysis of reporter constructs transfected into a mouse B cell line, Ba/F3. 74 However, while C/EBP activation is required for HIV-1 replication in monocytes, it is not necessary for HIV-1 replication in T cells, 72, 73 indicating that transcriptional regulation of HIV-1 is different in monocytes and T cells. Therefore, results of studies investigating HIV-1 transcriptional regulation using lymphoid lines may not reveal the mechanism of regulation of HIV-1 LTR transcription in monocytes. Consequently, more accurate insights into the mechanism of HIV-1 provirus activation in latently infected monocytes may be obtained by investigating transcriptional factor activation in primary monocyte/macrophages. In the current study, we examined the effect of GM-CSF and LPS on the induction of these transcription factors, NF-B, C/EBP, and Sp1, that were associated with the regulation of HIV-1 transcription in a human monocyte/macrophage cell line. 84 We demonstrated that while C/EBP and NF-B were markedly induced by 24 hr of stimulation with GM-CSF alone, the level of C/EBP and NF-B induced by GM-CSF alone was not further increased by additional stimulation with LPS. This observation suggested that the synergistic effect of LPS stimulation with GM-CSF treatment on HIV-1 production was not due to increased HIV-1 LTR activation mediated by C/EBP and NF-B induction. In contrast, while stimulation with GM-CSF or LPS alone minimally induced Sp1, the combination of GM-CSF and LPS markedly stimulated Sp1. Thus, activation of Sp1 may be the critical juncture for the synergistic stimulation by GM-CSF and LPS of HIV-1 production by JR-CSF mouse monocytes. Furthermore, activation of Sp1 may explain how GM-CSF and LPS can activate the HIV-1 LTR and induce robust HIV-1 replication despite the compromised function of Tat, the major positive regulator of HIV-1 gene expression, in mouse cells. The capacity of Tat to induce transcriptional elongation from the HIV-1 LTR and thereby amplify HIV-1 replication is reduced markedly in mouse cells because Tat cannot interact with the mouse homologue of human cyclin T1 to recruit an RNAP II transcription elongation complex to the trans-activation-responsive element in the 5Ј region of nascent transcripts. 85, 86 Nevertheless, we demonstrated that the LTR-regulated HIV-1 provirus in the transgene was highly responsive to stimulation by GM-CSF and even more so to the combination of GM-CSF and LPS. Sp1 activates the HIV-1 LTR by binding to three tandem Sp1 sites of variable affinity in the promoter region of HIV-1. 87 After binding to DNA, Sp1 has the unique capacity to robustly activate the HIV-1 LTR by binding to mouse cyclin T1 and recruiting the transcriptional complex to the preinitiation complex in the absence of Tat or TAR. 88 The robust replication of HIV-1 in rat cells whose cyclin T1 lacks the cysteine 261 residue present in human cyclin T1 that is required for forming the P-TEFb/Tat/TAR complex necessary for Tat-mediated transactivation was attributed to this Tat/TAR-independent mechanism. 88 Taken together, these data indicate that the combination of GM-CSF and LPS induces robust HIV-1 production by the JR-CSF mouse monocytes by inducing Sp1 and other transcription factors thereby enabling Tat/TAR independent activation of the HIV-1 LTR.
The crucial role of Sp1 in the activation of HIV-1 transcription may explain our finding that inhibition of either the ERK cascade or the p38 kinase pathway potently suppressed HIV-1 production by JR-CSF mouse monocytes. After stimulation of human macrophages with LPS, Sp1 transcription factor is activated both by the p38 MAP kinase pathway 89 and by MEK-mediated phosphorylation of threonines at positions 453 and 739. 90 Because Sp1 can be activated by both the ERK cascade and the p38 MAP kinase pathways, we propose that the combination of LPS and GM-CSF provides additive induction of Sp1 by activating both the ERK and p38 MAP kinase pathways. Activation of sufficient Sp1 by the combination of GM-CSF and LPS is then able to activate the HIV-1 LTR in a Tatindependent manner and induce HIV-1 production by JR-CSF mouse monocytes. The requirement for activation of both the ERK and p38 MAP kinase pathways for optimal activation of Sp1 would explain why inhibition of either pathway was sufficient to markedly inhibit HIV-1 production by JR-CSF mouse monocytes. Although the studies described in this paper were performed in mouse cells, the findings may have relevance in delineating a Tat-independent activation pathway induced by inflammatory and infectious stimuli that is responsible for the initial activation of latently infected monocytes that serve as a persistent reservoir capable of reintroducing HIV-1 infection into lymphoid tissues after the cessation of HAART. We are currently investigating this possibility. Thus, taken together the results of our studies delineate the signal transduction pathway of HIV-1 LTR activation by GM-CSF and LPS and indicate that JR-CSF transgenic mice may provide a new system for investigating the mechanism of activation of HIV-1 production from latently infected monocytes.
